Clinical Trials
14 trialsNCT06215118 2026-05-22
MagnetisMM-30
Pfizer
Phase 1 Recruiting
NCT05169515 2026-05-18
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
Hoffmann-La Roche
Phase 1 Recruiting
NCT06896916 2026-05-12
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
AbbVie
Phase 1 Recruiting
NCT05583617 2026-05-04
PLYCOM
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT04884035 2026-04-17
Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma
Celgene
Phase 1 Recruiting
NCT04975997 2026-04-03
EXCALIBER-RRMM
Celgene
Phase 3 Active not recruiting
NCT02773030 2026-03-20
A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma
Celgene
Phase 1/2 Active not recruiting
NCT05827016 2026-03-13
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
Bristol-Myers Squibb
Phase 3 Recruiting
NCT06121843 2026-02-18
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 1 Recruiting
NCT04855136 2025-09-11
KarMMa-7
Celgene
Phase 1/2 Terminated
NCT04464798 2025-04-29
A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas
Celgene
Phase 1 Terminated
NCT05289492 2024-10-26
Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma
iTeos Therapeutics
Phase 1 Terminated
NCT03310619 2024-04-04
PLATFORM
Celgene
Phase 1/2 Completed
NCT04882163 2021-10-05
Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma
Celgene
Phase 1/2 Withdrawn